110. Novel cell and gene therapies, Mark Gergen, CEO, Poseida Therapeutics, Inc.
Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022. He joined Poseida in February 2018, initially serving as Chief Business Officer and Chief Financial Officer before being n...
13 Jul 202229min
109. Gene therapy CDMO, Tim Miller, CEO, Erandi De Silva, SVP of Prod. Dev., Forge Biologics
Timothy J. Miller, Ph.D. CEO, President and Co-Founder Timothy Miller is CEO, President and Co-Founder of Forge Biologics, Inc., a VC-backed gene therapy development engine focused on accelerating ac...
29 Jun 202221min
108. Vibe Bio launches to transform drug development, Alok Tayi Ph.D. and Susanna Harris Ph.D.
Our guest this week is one of our hosts, Alok Tayi, and he has some exciting news. The official launch of his new company, Vibe Biotechnology, building a global community of patients, scientists, and...
22 Jun 202219min
107. Fighting infectious diseases with biologics, Paul Garofolo, Co-founder & CEO, Locus Biosciences
Paul is the CEO & Co-founder of Locus Biosciences. With a career that spans manufacturing, research & development, information technology and corporate transformations, Paul brings a broad range of ex...
15 Jun 202230min
106. Next-Gen CRISPR applications, Trevor Martin, Co-founder & CEO, Mammoth Biosciences
Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of ...
8 Jun 202225min
105. Gene therapy in hearing loss, Laurence Reid, PhD, CEO, Decibel Therapeutics
Laurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery and development opportunities. Before tha...
1 Jun 202237min
104. Embracing nerve repair, Karen Zaderej, CEO, Chairman, and President, Axogen
Ms. Zaderej has served as Axogen’s President, Chief Executive Officer, and a member of our Board of Directors since September 2011 and the Chairman of our Board of Directors since May 2018. Since May ...
25 Mai 202226min
103. Patient-driven thrombosis innovations, John Glasspool, CEO, Anthos Therapeutics
John Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics. Mr. Glasspool is also a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice P...
18 Mai 202224min
